BNTX vs REGN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
REGN Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while BNTX counters with relative strength in Valuation. Fundamentally, BNTX trades at 7.0x Forward P/E with -55.5% operating margin (-15.1% YoY revenue) versus REGN at 14.9x Forward P/E and 30.4% operating margin (+36.3% YoY). In options structure, BNTX sits in UNCLASSIFIED (76th %ile IV; Dealer Gamma Walls on Pro) against REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BNTX | REGN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $20.6B | $97.8B | Larger Scale | REGN |
| Trailing P/E Ratio Valuation | 7.0x | 20.9x | Lower Multiple | BNTX |
| Forward P/E Ratio Valuation | 7.0x | 14.9x | Lower Multiple | BNTX |
| Revenue Growth (YoY) Growth | -15.1% | +36.3% | Higher Growth | REGN |
| Operating Margin (TTM) Profitability | -55.5% | 30.4% | Higher Margin | REGN |
| Net Profit Margin Profitability | -60.9% | 28.5% | Higher Margin | REGN |
| Return on Equity (ROE) Capital Efficiency | -8.1% | 14.9% | Higher ROE | REGN |
| 52-Week Range Position Momentum | 4% ($80โ$124) | 83% ($592โ$992) | Stronger Trend | REGN |
| Beta / 30D Volatility Risk Regime | 0.81ฮฒ ยท 31% Vol | 0.32ฮฒ ยท 55% Vol | Lower Realized Risk | BNTX |
| Unified Institutional Score Composite Signal | 43.3 / 100 (HOLD) | 42.6 / 100 (HOLD) | Higher Composite | BNTX |